Valuing Specialty Chemicals (Premium P/E)

Start With Multiples That Survive Loss-Makers

Specialty chemicals carry a lasting valuation premium over basic chemicals, but only on normalised earnings (earnings at a normal point in the cycle) and only where the economics really are specialty. Trailing P/E gets the comparison wrong: in a downswing many chemical companies lose money and drop out of the average, leaving a figure built from the survivors. Compare on EV/EBITDA, and where you need a P/E, use the aggregate figure.

Damodaran Industry Multiples (Jan 2026)

Damodaran publishes two kinds of figure. A simple average takes each company’s own ratio and averages them; it misleads for three reasons. It counts only the companies that made money, 40.7% of the specialty group and 24.1% of the basic group. It weights each company equally. And a firm with barely positive earnings posts a ratio in the hundreds. An aggregate figure divides the group’s total value by its total earnings, so no small company can dominate.

*Basic chemicals’ forward earnings were depressed by the cycle in the Jan 2026 data, which lifts their ratio. It does not mean commodity producers are valued above specialty ones on normal earnings.

Screening Ranges and the Primer’s Figures

The illustrative figures are the ones the primer and its Excel model use; the ranges are conventions, not measurements. Where a company’s sales bridge shows it taking whatever price the market sets, the commodity figures are the right comparison.

ROIC Spread Links to the Multiple

A multiple above the basic-chemicals level rests on returns above the cost of capital. On Damodaran’s Jan 2026 industry figures specialty chemicals earned 3.70 points above their cost of capital and basic chemicals 2.50 points below it. No large specialty group files an FY2025 ROIC, so for a single company the spread has to be built from its accounts; the ROIC guide shows how.

When a Specialty Label Hides Commodity Pricing

A specialty label on the company does not make every segment specialty. At Albemarle in FY2025 net sales fell 4% to $5,143M while volume rose 7%, because lithium prices fell, and gross margin was 13.0% after 1.2% in FY2024. Its bromine business, by contrast, sells on performance. The price per kilogram that drives the lithium side is explained in the lithium carbonate vs hydroxide guide.

Value a segment like that on its cash flows at a stated long-run commodity price, and use a published multiple only as a cross-check. A basic-chemicals multiple is measured on trailing earnings that may be depressed. Apply it to earnings already restored to a long-run price and you count the recovery twice.

Worked Comparison: Formulation vs Commodity-Linked

Two fictional companies from the primer’s Excel model, each valued on a ten-year DCF at its own cost of capital:

Each cost of capital is built in the model from its own rate assumptions for that type of business, so neither matches Damodaran’s industry figures exactly. The lithium producer earns the higher margin once its price has recovered, yet its DCF value is a far smaller multiple of that EBITDA. Two things drive the gap. It starts at a low-point price below its cash cost and loses money in the first year. And even at the long-run price its return on capital sits below its cost of capital, so every dollar it reinvests to grow destroys value.

Evidence Before a Multiple

Check the filings before attaching any multiple: a positive price line in the sales bridge, a gross margin that holds through raw-material swings, and returns above the cost of capital.